# 2026年1月5日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. CD47阻断诱导的程序性坏死补充了BCL-2抑制诱导的凋亡在淋巴系统肿瘤中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484790)
**期刊：** Journal of hematology & oncology
**PMID：** 41484790
**DOI：** 10.1186/s13045-025-01774-3

### 第一部分 原文与翻译

**英文原标题：** CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究题目揭示了作者探索两种细胞死亡途径在淋巴系统恶性肿瘤治疗中的协同作用：通过阻断CD47诱导程序性坏死，同时结合BCL-2抑制剂诱导的细胞凋亡。此策略可能克服单一细胞死亡通路诱导后肿瘤细胞的存活逃逸问题。研究具有较强的机制创新性，为联合靶向疗法提供新的思路。但由于尚无摘要与实验细节，具体的模型验证和临床转化价值仍需进一步研究。

---

## 2. 泛癌种单细胞图谱揭示双阴性T细胞的异质性与功能多样性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484771)
**期刊：** Molecular cancer
**PMID：** 41484771
**DOI：** 10.1186/s12943-025-02548-8

### 第一部分 原文与翻译

**英文原标题：** A pan-cancer single cell landscape reveals heterogeneity and functional diversity of double-negative T cells.

> **英文摘要：**
> BACKGROUND: Double-Negative T (DNT) cells, lacking both CD4 and CD8 expression, play critical roles in cancer immunology, and have garnered increasing attention in cancer research. However, their heterogeneity and functional diversity within the tumor microenvironment (TME) remain underexplored.
> 
> METHODS: In-house and publicly available single-cell RNA sequencing (scRNA-seq) data for different cancer types were integrated after quality control and batch effect correction, followed by DNT cells separation from CD3 T cells subtypes. Functional characteristics, intercellular communication, differentiation trajectories, regulatory networks, and clinical relevance were analyzed among different DNT subsets. Key findings were validated using multiplex immunofluorescence and spatial transcriptomics to investigate the spatial localization of DNT subsets and their interactions within the TME. Impact of γδ T cells on immunotherapy response was also assessed using MC38-based murine tumor model.
> 
> RESULTS: By integrating scRNA-seq data from 2,369 samples across 23 cancer types, we established a comprehensive single-cell atlas of 157,025 high-quality DNT cells. Fourteen distinct DNT subsets (6 αβ DNT and 8 γδ T cell subsets) were identified, demonstrating tumor both type-specific and shared distribution patterns, as well as unique cell-cell interaction network within the TME. These subsets displayed specialized functional profiles, including cytotoxicity, antigen presentation, and immune modulation, indicating that the functional diversity of DNT cells is largely subset-specific rather than a manifestation of multifunctionality within a single population. We also delineated divergent trajectories for αβ DNT and γδ T cell subsets, including the functional plasticity of gut-resident γδ T cells transitioning between cytotoxic and immunosuppressive states. Notably, several DNT subsets were significantly associated with favorable clinical treatment outcomes, including improved responses to cancer immunotherapy. Consistently, depletion of γδ T cells in the murine tumor model significantly decreased the efficacy of PD-1 blockade, underscoring their critical role in therapeutic response.
> 
> CONCLUSIONS: Our study uncovers the previously underappreciated heterogeneity and functional diversity of DNT cells in the TME and demonstrates their profound impact on tumor progression and immunotherapy outcomes.

> **中文摘要：**
> 背景：双阴性T（DNT）细胞不表达CD4和CD8分子，在肿瘤免疫学中发挥关键作用，近年来逐渐受到癌症研究领域的重视。然而，其在肿瘤微环境（TME）中的异质性和功能多样性仍未得到充分探究。
> 
> 方法：研究整合了自有及公开来源的多种癌症类型的单细胞RNA测序（scRNA-seq）数据，经过质量控制和批次效应校正后，从CD3 T细胞亚型中分离出DNT细胞。随后分析了不同DNT细胞亚群的功能特征、细胞间通讯、分化轨迹、调控网络及其临床相关性。利用多重免疫荧光和空间转录组学验证关键发现，以探讨DNT细胞亚群在TME中的空间分布及其相互作用。此外，还通过基于MC38的小鼠肿瘤模型评估γδ T细胞对免疫治疗反应的影响。
> 
> 结果：通过整合来自23种癌症类型共2369个样本的scRNA-seq数据，研究构建了包含157,025个高质量DNT细胞的综合单细胞图谱。共鉴定出14个不同的DNT细胞亚群（包括6个αβ DNT亚群和8个γδ T细胞亚群），显示出既具有肿瘤类型特异性又具有共享分布特征，并在TME中形成独特的细胞间相互作用网络。这些亚群展现出特化的功能特征，包括细胞毒性、抗原呈递和免疫调节，提示DNT细胞的功能多样性主要由亚群特异性决定，而非单一群体的多功能表现。研究还描绘了αβ DNT和γδ T细胞亚群的不同分化轨迹，包括肠道驻留γδ T细胞在细胞毒性与免疫抑制状态之间转变的功能可塑性。值得注意的是，若干DNT细胞亚群与良好的临床治疗结局显著相关，包括对癌症免疫治疗的更佳反应。与此相一致，在小鼠肿瘤模型中耗竭γδ T细胞可显著降低PD-1阻断的治疗效果，进一步凸显其在免疫治疗响应中的关键作用。
> 
> 结论：本研究揭示了TME中DNT细胞此前未被充分认识的异质性与功能多样性，并证明其对肿瘤进展和免疫治疗效果具有深远影响。

### 第二部分 AI 大师评价

该研究利用泛癌种单细胞RNA测序大数据建立了迄今最全面的双阴性T细胞图谱，揭示了其在不同癌症中的分布模式和功能异质性。通过空间转录学与动物模型验证，作者厘清了αβ与γδ DNT细胞的分化轨迹及其与免疫治疗应答的关联，具有重要的肿瘤免疫学意义。研究创新性地说明DNT细胞功能多样性源于亚群差异而非单细胞多能性，为精准免疫干预提供了新思路。然而，其结果仍需在更大样本与临床环境中进一步验证。

---

## 3. 靶向STING诱导GSDMD依赖性细胞焦亡并增强肾细胞癌的抗肿瘤免疫反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484389)
**期刊：** Oncogene
**PMID：** 41484389
**DOI：** 10.1038/s41388-025-03671-y

### 第一部分 原文与翻译

**英文原标题：** Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma.

> **英文摘要：**
> While Stimulator-of-interferon genes (STING) is an innate immune adapter crucial for sensing cytosolic DNA and modulating immune microenvironment, its tumor-promoting role in tumor survival and immune evasion remains largely unknown. Here we reported that renal cancer cells are exceptionally dependent on STING for survival and evading immunosurveillance via suppressing ER stress-mediated pyroptosis. We found that STING is significantly amplified and upregulated in clear cell renal cell carcinoma (ccRCC), and its elevated expression is associated with worse clinical outcomes. Mechanically, STING depletion in RCC cells specifically triggers activation of the PERK/eIF2α/ATF4/CHOP pathway and activates cleavage of Caspase-8, thereby inducing GSDMD-mediated pyroptosis, which is independent of the innate immune pathway of STING. Moreover, animal study results revealed that STING depletion promoted infiltration of CD4 and CD8 T cells, consequently boosting robust antitumor immunity via pyroptosis-induced inflammation. From the perspective of targeted therapy, we found that Compound SP23, a PROTAC STING degrader, demonstrated comparable efficacy to STING depletion both in vitro and in vivo for treatment of ccRCC. These findings collectively unveiled an unforeseen function of STING in regulating GSDMD-dependent pyroptosis, thus regulating immune response in RCC. Consequently, pharmacological degradation of STING by SP23 may become an attractive strategy for treatment of advanced RCC.

> **中文摘要：**
> 尽管干扰素基因刺激因子（STING）作为一种先天免疫适配蛋白，在感知细胞质DNA及调节免疫微环境方面至关重要，但其在肿瘤生存和免疫逃逸中的促瘤作用仍 largely 未知。在本研究中，我们报道了肾癌细胞对STING在生存及免疫监视逃逸中的特殊依赖性，其机制是通过抑制内质网应激介导的细胞焦亡实现的。我们发现，在透明细胞肾细胞癌（ccRCC）中，STING显著扩增并上调，其高表达与较差的临床结局相关。从机制上看，敲除RCC细胞中的STING可特异性激活PERK/eIF2α/ATF4/CHOP通路并促进Caspase-8裂解，从而诱导GSDMD介导的细胞焦亡，而这一过程独立于STING的先天免疫信号通路。此外，动物实验结果显示，STING缺失促进了CD4和CD8 T细胞的浸润，并通过焦亡诱导的炎症反应显著增强了抗肿瘤免疫。从靶向治疗的角度，我们发现PROTAC降解剂SP23在体内外均表现出与STING缺失相当的治疗效果。这些发现共同揭示了STING在调控GSDMD依赖性细胞焦亡及调节RCC免疫反应中的意外功能，因此，通过SP23实现STING药理性降解可能成为治疗晚期RCC的潜在策略。

### 第二部分 AI 大师评价

该研究揭示STING在透明细胞肾细胞癌中具有促瘤功能，其通过抑制内质网应激介导的GSDMD依赖性细胞焦亡帮助肿瘤免疫逃逸。作者利用细胞和动物模型明确了STING耗竭可激活PERK/eIF2α/ATF4/CHOP通路并增强T细胞浸润及抗肿瘤免疫。研究进一步发现PROTAC降解剂SP23可模拟STING缺失作用，为晚期RCC的治疗提供了新的策略。该工作在机制上具有创新性，但未来仍需在人类样本及临床层面验证其安全性与可行性。

---

## 4. SLC25A15 转运蛋白在 ESR1 突变型乳腺癌肝转移形成中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484388)
**期刊：** Oncogene
**PMID：** 41484388
**DOI：** 10.1038/s41388-025-03640-5

### 第一部分 原文与翻译

**英文原标题：** The role of the SLC25A15 transporter in the formation of liver metastasis in ESR1-mutated breast cancer.

> **英文摘要：**
> Activating mutations in the ligand-binding domain of the estrogen receptor (ER)-encoding (ESR1) gene are present in up to 40% of metastatic breast cancer (BC) patients and are strongly associated with a high risk of liver metastasis (LM) formation. Using the MCF-7 BC model, we investigated whether the increased hepatic tropism of ESR1-mutated BC cells is driven by their metabolic adaptation to the liver microenvironment. Indeed, metabolomic analysis revealed elevated metabolites related to the urea cycle (UC) in LM-forming ESR1-mutated cells compared to wild-type (WT) ER-expressing cells, which failed to generate LM. The subsequent proteomic, western blotting, and qPCR analyses demonstrated a dramatic upregulation of the UC constituent, the mitochondrial ornithine/citrulline transporter SLC25A15, in liver-predilected ESR1-mutated cells relative to their WT counterpart cells. Unlike WT cells, ESR1-mutated cells readily formed spheroids and exhibited enhanced migration in liver mimicking hepatocyte-conditioned media. In addition, we employed a novel ex vivo approach where ESR1 mutated cells were seeded onto colonized fresh liver tissue-which was abolished by SLC25A15 knockout. Moreover, SLC25A15 knockout robustly reduced the ability of ESR1-mutated cells to establish LM in vivo. These findings highlight SLC25A15-mediated dysregulation of the UC as a critical driver of BC hepatic metastasis and identify SLC25A15 as a potential therapeutic target for disrupting metastatic spread of BC to the liver.

> **中文摘要：**
> 雌激素受体（ER）编码基因（ESR1）的配体结合域活化突变在多达 40% 的转移性乳腺癌（BC）患者中存在，并与肝转移（LM）形成的高风险显著相关。使用 MCF-7 乳腺癌模型，我们探讨了 ESR1 突变型乳腺癌细胞对肝脏微环境的代谢适应是否驱动其增强的肝脏趋向性。确实，代谢组学分析显示，与无法形成肝转移的野生型（WT）ER 表达细胞相比，能够形成肝转移的 ESR1 突变细胞中与尿素循环（UC）相关的代谢物水平升高。随后进行的蛋白质组学分析、西方印迹和 qPCR 检测表明，ESR1 突变的、具有肝脏偏向性的细胞中，线粒体鸟氨酸/瓜氨酸转运蛋白 SLC25A15（尿素循环成分之一）显著上调，而这种上调在 WT 对照细胞中未观察到。与 WT 细胞不同，ESR1 突变细胞能够容易形成类球体，并在模拟肝脏的肝细胞条件培养基中表现出增强的迁移能力。此外，我们采用了一种新型的离体模型，将 ESR1 突变细胞接种于已被定殖的新鲜肝组织上——而这一现象在 SLC25A15 敲除后被完全消除。此外，SLC25A15 敲除显著降低了 ESR1 突变细胞在体内建立肝转移的能力。这些结果强调了 SLC25A15 介导的尿素循环失调是乳腺癌肝转移的关键驱动因素，并将 SLC25A15 确定为干预乳腺癌向肝转移的重要潜在治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于 ESR1 突变型乳腺癌易发生肝转移的分子机制，发现线粒体转运蛋白 SLC25A15 在肝转移形成中的关键作用。作者通过代谢组、蛋白组及功能实验揭示，SLC25A15 上调导致尿素循环紊乱，从而促进肿瘤细胞在肝脏环境中的存活与迁移。SLC25A15 敲除显著抑制体内外肝转移形成，验证了其功能性。该研究创新性地将代谢重编程与器官特异性转移联系起来，但尚需在临床样本和治疗模型中进一步验证其转化潜力。

---

## 5. RNA解旋酶UPF1在复制依赖性组蛋白mRNA降解中的募集与调控机制洞见

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484129)
**期刊：** Nature communications
**PMID：** 41484129
**DOI：** 10.1038/s41467-025-67991-z

### 第一部分 原文与翻译

**英文原标题：** Mechanistic insights into recruitment and regulation of the RNA helicase UPF1 in replication-dependent histone mRNA decay.

> **英文摘要：**
> Metazoan histone mRNAs are a unique class of mRNAs that lack the poly(A) tail present in all other eukaryotic transcripts. Instead, they end in a conserved stem-loop (SL) structure, necessitating a decay mechanism that is distinct from deadenylation-initiated degradation. Here, combining structural and functional approaches, we elucidate molecular mechanisms of initiation of histone mRNA decay. At the end of S-phase, the RNA helicase UPF1, the exoribonuclease 3'hExo and stem-loop binding protein SLBP all contribute to histone mRNA degradation, although how they are mechanistically coupled remained unknown. The cryoEM structure of an UPF1:SL RNA complex, presented here, shows that binding of UPF1 partially melts the RNA stem in the absence of ATP, harnessing the free energy derived from RNA-binding to unwind RNA. This melting event primes the SL-RNA for decay by 3'hExo. Using biochemical and cellular analyses, we demonstrate that SLBP directly engages the UPF1 helicase core to attenuate its unwinding activity and prevent premature degradation. Activation of UPF1 at a later stage promotes SL-RNA decay. We provide direct evidence that UPF1, SLBP and 3'hExo form a degradosome-like assembly that functionally couples SL unwinding and degradation, highlighting a dynamic and intricate network of UPF1-centric interactions that orchestrates timely histone mRNA decay.

> **中文摘要：**
> 多细胞动物的组蛋白mRNA是一类独特的mRNA，它们缺乏存在于其他所有真核生物转录本中的poly(A)尾。相反，它们以一个保守的茎环（SL）结构结尾，这要求一种不同于去腺苷化启动的降解机制。在本研究中，我们结合结构学与功能学方法，阐明了组蛋白mRNA降解起始的分子机制。在S期末，RNA解旋酶UPF1、外切核糖核酸酶3'hExo以及茎环结合蛋白SLBP均参与组蛋白mRNA的降解，然而它们在机制上如何耦联尚不清楚。本研究报道的UPF1:SL RNA复合物冷冻电镜结构显示，在无ATP的情况下，UPF1的结合可部分熔解RNA茎结构，利用RNA结合产生的自由能来解开RNA。该熔解事件为3'hExo介导的SL-RNA降解作好准备。通过生化与细胞学分析，我们发现SLBP可直接与UPF1的解旋酶核心相互作用，减弱其解旋活性并防止过早降解。后期UPF1的激活则促进SL-RNA的降解。我们提供了UPF1、SLBP与3'hExo形成类似核糖体降解复合体的直接证据，该复合体将SL解链与降解过程功能性耦合，揭示了一个以UPF1为核心、动态且复杂的相互作用网络，协调组蛋白mRNA的及时降解。

### 第二部分 AI 大师评价

该研究以复制依赖性组蛋白mRNA的降解为研究对象，结合冷冻电镜解析与生化实验，从结构与功能层面揭示UPF1在降解起始阶段的关键作用。作者发现UPF1可在无ATP情况下利用结合能部分解开RNA茎环结构，并与SLBP及3'hExo协同形成类似降解酶复合体。此工作首次直接展示了UPF1中心的动态调控机制，为理解真核特异mRNA降解提供了重要分子依据。研究创新性强，但对复合体在体内动态调控的时空特征尚需进一步探索。

---

## 6. Binimetinib 和 Encorafenib 治疗携带非 V600E 型 BRAF 突变的晚期实体瘤：II 期 BEAVER 试验结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484121)
**期刊：** Nature communications
**PMID：** 41484121
**DOI：** 10.1038/s41467-025-68076-7

### 第一部分 原文与翻译

**英文原标题：** Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

> **英文摘要：**
> Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types. Currently, there are no established targeted therapies with proven efficacy for cancers with non-V600E BRAF mutations. We developed the investigator-initiated, Phase II BEAVER clinical trial (NCT03839342) to evaluate the efficacy of BRAF and MEK inhibitors in patients with non-V600E BRAF mutations. The primary outcome was objective response rate (ORR). The best ORR was 14% (3/21), the primary endpoint was not met. By analyzing genomic data from patient tumors, circulating tumor DNA (ctDNA), patient-derived xenograft (PDX) models generated from enrolled patients, and Class 2 & 3 BRAF mutant cell lines, we discovered MAPK-dependent and independent mechanisms of resistance to BRAF/MEK inhibition. These mechanisms include the acquisition of new mutations in NRAS, MAP2K1, RAF1, and RB in ctDNA at the time of disease progression. CDK4/6 and SHP2 emerge as mediators of intrinsic resistance to BRAF/MEK inhibition in Class 2 & 3 BRAF mutant tumors. Therapeutic strategies combining CDK4/6 or SHP2 inhibitors with BRAF/MEK inhibitors in preclinical models show greater efficacy than BRAF/MEK inhibitors alone in these cancers.

> **中文摘要：**
> Ⅱ型和Ⅲ型非 V600E 型 BRAF 突变是在多种癌症类型中驱动肿瘤发生的致癌因素。目前，尚无已确立且具有确切疗效的针对非 V600E 型 BRAF 突变癌症的靶向治疗。我们开展了一项由研究者发起的Ⅱ期 BEAVER 临床试验（NCT03839342），以评估 BRAF 与 MEK 抑制剂在携带非 V600E 型 BRAF 突变的患者中的疗效。主要结局指标为客观缓解率（ORR）。最佳 ORR 为 14%（3/21），未达到主要终点。通过分析患者肿瘤的基因组数据、循环肿瘤 DNA（ctDNA）、受试者来源的异种移植瘤（PDX）模型以及Ⅱ型与Ⅲ型 BRAF 突变细胞系，我们发现了依赖 MAPK 通路及非依赖 MAPK 通路的 BRAF/MEK 抑制耐药机制。这些机制包括在疾病进展时 ctDNA 中出现新的 NRAS、MAP2K1、RAF1 和 RB 突变。CDK4/6 和 SHP2 被发现是Ⅱ型与Ⅲ型 BRAF 突变肿瘤对 BRAF/MEK 抑制剂产生内在耐药的关键介导因子。在临床前模型中，将 CDK4/6 或 SHP2 抑制剂与 BRAF/MEK 抑制剂联合使用的治疗策略，较单用 BRAF/MEK 抑制剂表现出更强的抗肿瘤疗效。

### 第二部分 AI 大师评价

本研究旨在探索非 V600E 型 BRAF 突变癌症的靶向治疗可能性，评估 BRAF 与 MEK 抑制联合方案的疗效。虽然 II 期 BEAVER 试验的主要终点未达标，但科研团队通过多层次的基因组数据和模型研究揭示了耐药的分子机制。研究发现 NRAS、MAP2K1、RAF1 与 RB 的新突变及 CDK4/6、SHP2 信号参与耐药过程，为未来联合抑制策略提供了合理方向。研究创新性在于整合临床与分子机制分析，但受样本量及疗效限制，尚需进一步验证。

---

## 7. 紧密连接高表达且CDH17阳性的细胞群是结直肠癌肝转移的来源

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484106)
**期刊：** Nature communications
**PMID：** 41484106
**DOI：** 10.1038/s41467-025-68169-3

### 第一部分 原文与翻译

**英文原标题：** Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases.

> **英文摘要：**
> Colorectal cancer (CRC) frequently develops aggressive metastatic disease, yet the cellular features that enable dissemination remain poorly defined. IKKα, a kinase traditionally linked to stress and inflammatory signaling, is increasingly recognized for broader functions in cancer. Here, we show that loss of IKKα unexpectedly promotes metastasis in CRC. Using patient-derived organoids, we find that genetic or pharmacological inhibition of IKKα stabilizes tight-junction components, leading to the emergence of compact epithelial clusters with a heightened ability to spread and colonize the liver. Single-cell transcriptomics reveals expansion of a CDH17⁺/CLDN2⁺ epithelial subpopulation that dominates metastatic lesions, a finding validated by tissue staining. Remarkably, disrupting CLDN2 completely eliminates the metastatic advantage caused by IKKα loss. These results identify a metastasis-competent epithelial state driven by tight-junction remodeling and uncover a vulnerable node that may be exploited therapeutically in aggressive colorectal cancer.

> **中文摘要：**
> 结直肠癌（CRC）常发展为侵袭性转移性疾病，但促使其扩散的细胞特征尚不清楚。IKKα是一种传统上与应激和炎症信号相关的激酶，近年来被认为在癌症中具有更广泛的功能。本研究显示，IKKα的缺失出人意料地促进了CRC的转移。通过患者来源的类器官，我们发现对IKKα进行基因学或药理学抑制可稳定紧密连接成分，导致具有更强扩散和肝脏定植能力的致密上皮细胞簇出现。单细胞转录组学显示，一个CDH17⁺/CLDN2⁺的上皮亚群显著扩增，并在转移性病灶中占主导地位，组织染色验证了这一发现。值得注意的是，破坏CLDN2可完全消除IKKα缺失所引发的转移优势。这些结果揭示了一种由紧密连接重塑驱动的具转移潜能的上皮状态，并确定了一个可在侵袭性结直肠癌中用于治疗干预的脆弱节点。

### 第二部分 AI 大师评价

本研究揭示了IKKα作为结直肠癌转移调控关键因子的意外作用，利用患者来源类器官和单细胞转录组学从细胞状态层面阐明了紧密连接重塑与肝转移形成的关系。作者发现IKKα抑制会促进CDH17⁺/CLDN2⁺上皮亚群扩增并增强转移能力，而破坏CLDN2可完全消除这一效应。研究创新地提出了“紧密连接高表达上皮状态”作为具备转移能力的细胞谱系，为转移机制研究与靶向治疗提供了新方向。其局限性在于仍需进一步验证该机制在体内免疫微环境中的适用性。

---

## 8. 通过基于片段的抑制剂先导物发现揭示 WRN 的结构柔性特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484101)
**期刊：** Nature communications
**PMID：** 41484101
**DOI：** 10.1038/s41467-025-66768-8

### 第一部分 原文与翻译

**英文原标题：** WRN structural flexibility showcased through fragment-based lead discovery of inhibitors.

> **英文摘要：**
> WRN helicase is an established synthetic lethal target for inhibition in the treatment of microsatellite instability-high (MSI-H) and mismatch repair deficient (MMRd) cancers. The identification of helicase inhibitors is challenging as high-throughput biochemical screening campaigns typically return few validated hits that are often inactive in cell-based assays. Herein, we highlight the power of non-covalent fragment-based lead discovery in locating new druggable allosteric sites on WRN, enabling us to bypass the challenging behavior of WRN during high-throughput screening hampering hit identification. During the fragment optimization process, structures of WRN with key prioritized fragments reveal multiple conformations of WRN with significant domain rotations up to 180°, including a WRN conformation not previously described. Rooted in a combination of biochemical, biophysical, and structural approaches, we present the detailed analyses of optimized chemical matter evolved from screening hits and the unique ability of WRN to accommodate diverse conformations as detailed by structural characterization.

> **中文摘要：**
> WRN 解旋酶是治疗微卫星不稳定性高（MSI-H）和错配修复缺陷（MMRd）癌症中公认的合成致死性抑制靶点。解旋酶抑制剂的鉴定具有挑战性，因为高通量生化筛选活动通常仅能获得少量经验证的命中，并且这些化合物在细胞水平检测中往往缺乏活性。在本研究中，我们强调了非共价基于片段的先导化合物发现方法在定位 WRN 上新的可成药别构位点方面的优势，使我们能够绕过 WRN 在高通量筛选中表现出的复杂特性，从而避免命中鉴定受阻。在片段优化过程中，WRN 与关键优选片段结合的结构揭示了 WRN 的多种构象，显示出高达 180° 的显著结构域旋转，包括一种此前未被描述的 WRN 构象。基于生化、生物物理及结构学方法的综合应用，我们对从筛选命中优化而来的化学实体进行了详细分析，并揭示了 WRN 在结构表征中表现出的适应多样构象的独特能力。

### 第二部分 AI 大师评价

本研究以 WRN 解旋酶为研究焦点，采用非共价基于片段的先导物发现策略，揭示了其结构柔性及多样构象。作者通过结构、生物化学与生物物理结合的综合分析，不仅发现了新的可成药别构位点，还首次报道了 WRN 前所未见的构象特征。该研究在突破传统高通量筛选局限的同时，为 MSI-H 与 MMRd 癌症药物研发提供了新方向。其创新性在于将片段优化与结构解析紧密结合，但后续仍需在细胞与体内模型中验证抑制剂的有效性与安全性。

---

## 9. 一种经工程化改造的可溶性融合前构象稳定化EB病毒gB抗原的结构与免疫原性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484092)
**期刊：** Nature communications
**PMID：** 41484092
**DOI：** 10.1038/s41467-025-67969-x

### 第一部分 原文与翻译

**英文原标题：** Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen.

> **英文摘要：**
> Epstein-Barr virus (EBV), the causative agent of mononucleosis, is linked to over 140,000 annual cancer-related deaths globally and increases the risk of multiple sclerosis by up to 32-fold. As a herpesvirus, EBV establishes lifelong infection, and over 90% of U.S. adults are EBV-seropositive. Despite its significant disease burden, no approved EBV vaccines or therapeutics exist. Among EBV envelope glycoproteins, the fusion protein (gB) is strictly required for epithelial and B cell infection. Here, using a combination of AlphaFold-guided modeling, rational design, and ThermoMPNN-informed optimization, we engineer a stabilized prefusion gB variant, C3-GT. This construct incorporates two inter-protomeric disulfide bonds and three cavity-filling substitutions, resulting in a melting temperature of 54 °C. Cryo-EM analysis of this construct reveals the prefusion structure of EBV gB, providing insights into the structural transitions required to adopt the postfusion conformation. Murine immunizations and depletion studies with human sera suggest a trend toward improved functional immunogenicity of C3-GT compared to postfusion gB. Collectively, these studies define engineering principles to stabilize class III fusion proteins, provide reagents to interrogate the human antibody response to EBV gB, and lay a foundation for further studies to develop EBV gB-based vaccine candidates.

> **中文摘要：**
> Epstein-Barr病毒（EBV）是传染性单核细胞增多症的病原体，每年与全球超过14万例癌症相关死亡有关，并使多发性硬化症的风险增加多达32倍。作为一种疱疹病毒，EBV可建立终身感染，美国超过90%的成年人对EBV呈血清阳性。尽管其疾病负担重大，但目前尚无获批的EBV疫苗或治疗药物。在EBV包膜糖蛋白中，融合蛋白（gB）是上皮细胞和B细胞感染所必需的关键因子。在本研究中，研究者结合AlphaFold引导的建模、理性设计和ThermoMPNN优化方法，构建了一种稳定化的融合前构象gB变体C3-GT。该构建体包含两个亚原体间二硫键和三个填充空腔的氨基酸替换，使其熔解温度达到54 °C。冷冻电镜分析显示了EBV gB的融合前结构，从而揭示了其向融合后构象转变所需的结构变化。小鼠免疫实验以及人血清消耗实验显示，相对于融合后gB，C3-GT在功能性免疫原性方面具有改善趋势。总体而言，这些研究定义了III类融合蛋白稳定化的工程化原则，提供了研究EBV gB人源抗体反应的实验工具，并为基于EBV gB的疫苗候选物开发奠定了基础。

### 第二部分 AI 大师评价

本研究旨在通过结构生物学与蛋白工程手段优化EB病毒关键融合蛋白gB的构象稳定性，提升其作为疫苗抗原的免疫原性。研究者利用AlphaFold与ThermoMPNN等AI指导方法设计出C3-GT变体，并通过冷冻电镜解析获得其融合前结构。实验结果表明该变体热稳定性显著提升，且在动物模型中呈现出更优的功能性免疫应答。这项工作不仅揭示了EBV gB的构象转换机制，也为稳定化III类融合蛋白及设计EBV疫苗提供了新的工程学思路。其潜在局限在于动物实验结果尚需在人类系统中验证。

---

## 10. 诊断时骨髓中非克隆性浆细胞比例升高与多发性骨髓瘤患者预后改善相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484090)
**期刊：** Blood cancer journal
**PMID：** 41484090
**DOI：** 10.1038/s41408-025-01449-9

### 第一部分 原文与翻译

**英文原标题：** Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma.

> **英文摘要：**
> In newly diagnosed multiple myeloma (NDMM), current risk stratification relies on cytogenetics and disease burden, but emerging immune parameters may refine prognosis. While a higher non-clonal plasma cell fraction (NCPF) predicts favorable outcomes in smoldering myeloma, its relevance in NDMM remains unexplored. We retrospectively analyzed 798 patients with NDMM where baseline bone marrow aspirates were tested to determine the NCPF, defined as the proportion of non-clonal plasma cells among total plasma cells. An NCPF ≥ 5% defined the NCPF-Enriched group. NCPF-High was observed in 124 patients (15.5% of all cohort). Compared to NCPF-Low, NCPF-Enriched patients had lower overall bone marrow plasma cell burden (median 20% vs. 50%, p < 0.0001), higher rates of hyperdiploidy (71% vs. 59%, p = 0.025), and similar cytogenetic risk. Six-year overall survival (OS) was significantly higher in NCPF-Enriched (70.3% vs. 56.5%, p = 0.0096), with independent prognostic value in multivariable analysis (HR 0.64, p = 0.03). Progression-free survival was also superior (HR 0.69, p = 0.006) in the NCPF-Enriched cohort in the setting of comparable treatment approaches. A higher non-clonal plasma cell fraction at diagnosis is independently associated with improved outcomes in NDMM, highlighting its potential as a novel immune prognostic biomarker warranting further investigation.

> **中文摘要：**
> 在新诊断的多发性骨髓瘤（NDMM）中，当前的风险分层依赖于细胞遗传学和疾病负担，但新出现的免疫参数可能进一步优化预后评估。尽管较高的非克隆性浆细胞比例（NCPF）被认为可预测惰性骨髓瘤的良好结局，但其在NDMM中的意义尚未探明。我们回顾性分析了798例NDMM患者，对其基线骨髓抽吸物进行检测以确定NCPF，NCPF定义为总浆细胞中非克隆性浆细胞所占比例。NCPF ≥ 5%的患者被定义为NCPF富集组。共有124名患者（占全部队列的15.5%）被归入NCPF高表达组。与NCPF低组相比，NCPF富集组患者总体骨髓浆细胞负荷较低（中位数20% vs. 50%，p < 0.0001），高倍体发生率更高（71% vs. 59%，p = 0.025），而细胞遗传学风险相似。六年总生存率（OS）在NCPF富集组中显著更高（70.3% vs. 56.5%，p = 0.0096），且在多变量分析中具有独立的预后价值（HR 0.64，p = 0.03）。在治疗方案相当的情况下，NCPF富集组的无进展生存期也更长（HR 0.69，p = 0.006）。诊断时较高的非克隆性浆细胞比例与NDMM患者更好的预后独立相关，提示其有作为新型免疫预后生物标志物的潜力，值得进一步研究。

### 第二部分 AI 大师评价

该研究旨在探讨新诊断多发性骨髓瘤患者骨髓中非克隆性浆细胞比例对预后的影响。研究者回顾性分析了近800例患者，通过定量NCPF评价其与临床特征及生存结局的关联。结果显示，NCPF ≥ 5%的患者具有更高的总生存率与无进展生存率，并在多变量分析中保持独立的预后价值。该发现揭示NCPF可能为新的免疫相关预后指标，为风险分层体系的优化提供了新思路，但仍需前瞻性研究验证其临床应用价值。

---

## 11. 损伤诱导的细胞焦亡通过激活嘌呤能受体P2Y2驱动内源性胸腺再生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484087)
**期刊：** Cell death & disease
**PMID：** 41484087
**DOI：** 10.1038/s41419-025-08345-x

### 第一部分 原文与翻译

**英文原标题：** Damage-induced pyroptosis drives endogenous thymic regeneration by activating the purinergic receptor P2Y2.

> **英文摘要：**
> T cell recovery is critical following damage, such as hematopoietic cell transplantation (HCT), with increased reconstitution associated with improved clinical outcomes. Endogenous thymic regeneration, a crucial process for restoring immune competence following cytoreductive therapies such as HCT conditioning, is often delayed, limiting T cell reconstitution. Fully understanding the molecular mechanisms driving regeneration is therefore crucial for uncovering therapeutic targets that can be exploited to enhance thymic function. Here, we identified that CD4+ CD8+ thymocytes rapidly and acutely undergo lytic cell death, specifically pyroptosis, following acute damage caused by ionizing radiation, and release damage-associated molecular patterns (DAMPS) into the thymic microenvironment, including ATP. Extracellular ATP stimulates the P2Y2 purinergic receptor on thymic epithelial cells (TECs)-a stromal cell crucial for supporting T cell development-resulting in the upregulation FOXN1, the master TEC transcription factor. Targeting the P2Y2 receptor with a P2Y2 agonist, UTPγS, promotes rapid regeneration of the TEC compartment in vivo following acute damage. These findings reveal a novel damage-sensing mechanism employed by the thymus where thymocytes adopt an alternative cell death mechanism which promotes thymic repair via P2Y2 signaling in TECs. This work identifies P2Y2 as a promising therapeutic target for enhancing thymus regeneration and improving immune recovery after HCT.

> **中文摘要：**
> 在经历损伤（如造血细胞移植，HCT）后，T细胞的恢复至关重要，其重建程度的提高与更佳的临床结局相关。内源性胸腺再生是细胞减少性治疗（如HCT预处理）后恢复免疫能力的关键过程，但常常延迟，从而限制T细胞的重建。因此，充分理解驱动再生的分子机制对于揭示可用于增强胸腺功能的治疗靶点至关重要。本研究发现，在电离辐射引起的急性损伤后，CD4+ CD8+胸腺细胞会迅速并急性地经历溶解性细胞死亡，具体为焦亡，并将包括ATP在内的损伤相关分子模式（DAMPs）释放到胸腺微环境中。胞外ATP刺激胸腺上皮细胞（TECs）上的P2Y2嘌呤能受体——一种支持T细胞发育的重要基质细胞，导致胸腺上皮细胞主转录因子FOXN1的上调。以P2Y2受体激动剂UTPγS为靶点，可在急性损伤后促进体内胸腺上皮细胞群的快速再生。这些发现揭示了胸腺采用的一种新型损伤感知机制，即胸腺细胞通过替代性细胞死亡机制，经由TECs中的P2Y2信号通路促进胸腺修复。本研究确定P2Y2是增强胸腺再生及改善HCT后免疫恢复的一个有前景的治疗靶点。

### 第二部分 AI 大师评价

该研究旨在阐明胸腺在急性损伤后再生的分子机制，重点揭示了细胞焦亡在胸腺修复过程中的作用。作者通过辐射损伤模型发现，CD4+CD8+胸腺细胞焦亡释放ATP，激活胸腺上皮细胞的P2Y2受体，从而上调FOXN1并促进胸腺组织再生。进一步，P2Y2受体激动剂UTPγS在动物模型中加速了胸腺重建。该研究创新性地揭示了胸腺内自体修复的信号通路，为造血细胞移植后的免疫重建提供了新的干预靶点，但机制的时间依赖性与不同损伤类型下的普适性尚需进一步研究。

---

## 12. 在CD8αβ共受体中嵌入CD28胞内信号尾部可增强TCR工程化T细胞功能且不依赖于实体瘤相关共刺激配体。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484084)
**期刊：** Nature communications
**PMID：** 41484084
**DOI：** 10.1038/s41467-025-67446-5

### 第一部分 原文与翻译

**英文原标题：** A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands.

> **英文摘要：**
> Adoptive transfer of T cells engineered with tumor-specific T cell receptors (TCRs) has shown limited efficacy in solid tumors, hindered by insufficient persistence, tumor trafficking, and dependence on tumor-associated co-stimulatory ligands. In a phase I trial (NCT04639245) for patients with metastatic MAGE-A1-expressing tumors and adequate organ function; one participant received treatment, which was well-tolerated. In this case and NSG murine models, infusion of CD4/CD8 T cells co-expressing a class-I MAGE-A1-specific TCR and CD8αβ, failed to control tumor progression. To enhance function downstream of TCR signaling, here we investigate the adaptability of TCR components to synthetic modification. Leveraging the obligate co-expression of CD8αβ required for class-I TCR function in CD4 T cells, we identify CD8β as a tractable site for engineering without loss of function. In vitro screening demonstrates incorporation of the CD28 intracellular tail, yielding a CD8/CD28 chimeric co-receptor, most effectively enhances cytokine production, T cell persistence, and tumor control in immunodeficient murine models while preserving stem-like transcriptional features compared to native CD8β. Further rational modification of the CD28 binding motifs improves tumor control in vivo with increased intratumoral accumulation and reduced exhaustion. This benefit also extends to PRAME and WT1-specific TCRs in vitro supporting generalizability.

> **中文摘要：**
> 以肿瘤特异性T细胞受体（TCR）工程化的T细胞的过继转移在实体瘤中的疗效有限，主要受制于T细胞持续性不足、肿瘤浸润能力差以及对肿瘤相关共刺激配体的依赖。在一项针对转移性MAGE-A1表达肿瘤且器官功能良好的患者的I期临床试验（NCT04639245）中，有一名参与者接受了治疗，并且耐受性良好。在该病例及NSG小鼠模型中，输注共表达I类MAGE-A1特异性TCR和CD8αβ的CD4/CD8 T细胞未能控制肿瘤进展。为增强TCR信号下游的功能，本研究探索了TCR组分的合成修饰可塑性。利用CD4 T细胞中I类TCR功能所必需的CD8αβ共表达特性，我们确定CD8β是一个可在不丧失功能的情况下进行工程化改造的靶点。体外筛选结果显示，将CD28胞内尾部嵌入CD8β形成的CD8/CD28嵌合共受体，能最有效地增强细胞因子产生、T细胞持续性以及在免疫缺陷小鼠模型中的肿瘤控制能力，同时较原生CD8β保持干样转录特征。进一步对CD28结合基序进行合理修饰后，可在体内提高肿瘤控制效应，伴随更高的肿瘤内积聚和更低的衰竭水平。这一改造效应在体外同样扩展至PRAME和WT1特异性TCR，支持其普适性。

### 第二部分 AI 大师评价

该研究探讨了通过在CD8β共受体中引入CD28胞内信号结构域来增强TCR工程化T细胞功能的新策略，旨在克服实体瘤免疫治疗中对共刺激信号依赖的限制。作者证明该CD8/CD28嵌合共受体可显著改善细胞因子产生、持久性及肿瘤控制能力。进一步的结构优化提升了体内抗肿瘤活性，并减少了T细胞耗竭。该研究创新性地实现了共受体信号系统重编程，为提升TCR治疗的普适性与疗效提供了新方向，但仍需在更多临床模型中验证长期安全性与疗效。

---

## 13. 抗CSF-1R治疗联合免疫化疗协同诱导适应性免疫反应以清除富含巨噬细胞的三阴性乳腺癌。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484081)
**期刊：** Nature communications
**PMID：** 41484081
**DOI：** 10.1038/s41467-025-67964-2

### 第一部分 原文与翻译

**英文原标题：** Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

> **英文摘要：**
> Women diagnosed with metastatic triple negative breast cancer (mTNBC) have limited treatment options, are more prone to develop resistance and are associated with high mortality. A cold tumor immune microenvironment (TIME) characterized by low T cells and high tumor associated macrophages (TAMs) in mTNBC is associated with the failure of standard-of-care chemotherapy and immune checkpoint blockade (ICB) treatment. We demonstrate that the combination of immunomodulatory low-dose Cyclophosphamide (CTX) coupled with anti-CSF-1R antibody targeted therapy (SNDX-ms6352) and anti-PD-1 (ICB), was highly effective against aggressive metastatic Trp53 null TNBC transplantable syngeneic models that present with high macrophage infiltration. Mechanistically, CSF-1R inhibition along with CTX disrupted the M-CSF/CSF-1R axis which upregulated IL-17, IL-5 and type II interferon resulting in elevated B- and T cell infiltration. Addition of an anti-PD-1 maintenance dose helped overcome de novo PD-L1 intra-tumoral heterogeneity (ITH) associated recurrence in lung and liver mTNBC.

> **中文摘要：**
> 被诊断为转移性三阴性乳腺癌（mTNBC）的女性治疗选择有限，更易产生耐药性，并且与高死亡率相关。mTNBC中的一种“冷”肿瘤免疫微环境（TIME），其特征是T细胞数量低而肿瘤相关巨噬细胞（TAMs）含量高，这与标准化疗和免疫检查点抑制（ICB）治疗失败有关。我们发现，免疫调节性低剂量环磷酰胺（CTX）联合抗CSF-1R抗体靶向治疗（SNDX-ms6352）及抗PD-1（ICB）的组合，对具有高巨噬细胞浸润的高度侵袭性转移性Trp53缺失TNBC可移植同系模型表现出极高的疗效。从机制上看，CSF-1R抑制与CTX联用破坏了M-CSF/CSF-1R轴，从而上调IL-17、IL-5和Ⅱ型干扰素，导致B细胞和T细胞浸润增加。补充抗PD-1维持剂量有助于克服与肺部和肝脏mTNBC复发相关的肿瘤内PD-L1异质性（ITH）所导致的新生耐药性。

### 第二部分 AI 大师评价

该研究针对转移性三阴性乳腺癌的免疫“冷”状态，提出了一种低剂量环磷酰胺联合抗CSF-1R及抗PD-1治疗的新策略。研究通过同系小鼠模型验证该联合方案可增强适应性免疫反应，显著增加B/T细胞浸润并抑制肿瘤生长。从机制上揭示了阻断M-CSF/CSF-1R轴在重塑免疫微环境中的关键作用。研究创新性地提出了多层免疫调控组合治疗思路，但仍需进一步临床验证其安全性与可推广性。

---

## 14. SOX4-STAT6-MTHFD2轴驱动肝细胞癌进展及治疗耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484064)
**期刊：** Cell death & disease
**PMID：** 41484064
**DOI：** 10.1038/s41419-025-08394-2

### 第一部分 原文与翻译

**英文原标题：** SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is a major global health burden. Despite recent advances in immunotherapy, tyrosine kinase inhibitors (TKIs) treatment or combined therapies, therapeutic resistance and disease progression remain significant challenges. SOX4, a transcription factor frequently overexpressed in HCC and other cancers, has been linked to drug resistance and poor prognosis; however, the underlying molecular mechanisms remain unexplored. In this study, we identify STAT6 as a novel transcriptional target and interacting partner of SOX4 in HCC cells. Genetic ablation or knockdown of SOX4 induced hypermethylation of the STAT6 promoter, suppressing its expression, while treatment with the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine restored STAT6 levels, indicating an epigenetic mechanism of regulation. In addition, SOX4 is physically associated with STAT6, as confirmed by co-immunoprecipitation and immunofluorescence. SOX4 depletion impaired interleukin-4 (IL-4)-induced phosphorylation of STAT6 at tyrosine residue 641 (Y641), implicating SOX4 in IL-4-mediated STAT6 activation. Chromatin immunoprecipitation (ChIP) assays demonstrated that SOX4 and STAT6 co-occupy the promoter of MTHFD2, a key enzyme in folate metabolism, regulating NADH/NADPH production and nucleotide biosynthesis. Knockdown of SOX4 or STAT6, or mutation of their binding sites within the MTHFD2 promoter, reduced MTHFD2 expression, NADPH levels, and nucleotide synthesis. Transcriptomic analyses from TCGA-LIHC and our independent cohort revealed a strong positive correlation between SOX4, STAT6, and MTHFD2, with MTHFD2 overexpression linked to poor overall survival. Clinically, elevated SOX4/STAT6/MTHFD2 axis activity was associated with resistance to immunotherapy or TKIs, either in our enrolled cohort or transcriptome data obtained from GSE109211. Metabolomic profiling further revealed increased NADPH and nucleotide biosynthesis in tumors with high SOX4/STAT6/MTHFD2 expression. Targeting STAT6 or MTHFD2 suppressed tumor growth in TKIs-resistant patient-derived xenograft models. Collectively, our findings identify the SOX4-STAT6-MTHFD2 axis as a critical driver of HCC progression and therapeutic resistance, offering a promising target for intervention in refractory HCC.

> **中文摘要：**
> 肝细胞癌（HCC）是全球主要的健康负担。尽管近年来免疫治疗、酪氨酸激酶抑制剂（TKIs）治疗以及联合疗法已有显著进展，但治疗耐药性和疾病进展仍是重要挑战。SOX4是一种在HCC及多种癌症中过度表达的转录因子，与药物耐受和预后不良有关；然而，其潜在的分子机制尚未被阐明。在本研究中，我们发现STAT6是HCC细胞中SOX4的新型转录靶基因及相互作用伴侣。SOX4的基因敲除或下调会诱导STAT6启动子的高甲基化，从而抑制其表达，而DNA甲基转移酶抑制剂5-Aza-2'-脱氧胞苷的处理可恢复STAT6的水平，提示存在表观遗传学调控机制。此外，共免疫沉淀和免疫荧光实验证实，SOX4与STAT6存在物理结合。SOX4的耗竭会削弱白细胞介素4（IL-4）诱导的STAT6在酪氨酸残基641（Y641）处的磷酸化，提示SOX4参与IL-4介导的STAT6激活。染色质免疫沉淀（ChIP）实验表明，SOX4和STAT6共同占据MTHFD2的启动子区域，MTHFD2是叶酸代谢的重要酶，调控NADH/NADPH的生成及核苷酸生物合成。敲低SOX4或STAT6，或突变其在MTHFD2启动子内的结合位点，均可降低MTHFD2表达、NADPH水平及核苷酸合成。来自TCGA-LIHC及独立队列的转录组分析揭示SOX4、STAT6与MTHFD2之间存在显著正相关，且MTHFD2过表达与总生存期较差相关。在临床上，SOX4/STAT6/MTHFD2轴活性升高与免疫治疗或TKIs耐药有关，无论是在研究队列还是GSE109211转录组数据中均可验证。代谢组学分析进一步发现，SOX4/STAT6/MTHFD2高表达肿瘤中NADPH与核苷酸生物合成增强。靶向STAT6或MTHFD2可抑制TKIs耐药患者来源异种移植模型的肿瘤生长。综上所述，我们的研究确认SOX4-STAT6-MTHFD2轴是推动HCC进展与治疗耐药的关键驱动因素，为难治性HCC的干预提供了有前景的靶点。

### 第二部分 AI 大师评价

本研究揭示了SOX4-STAT6-MTHFD2信号轴在肝细胞癌进展与治疗耐药中的核心作用，首次明确SOX4通过调控STAT6甲基化及其转录活性影响MTHFD2表达及代谢重编程。研究综合应用基因编辑、表观遗传学、转录组与代谢组分析，并结合临床样本与PDX模型，验证了该轴在HCC中的关键生物学功能。结果指出干预STAT6或MTHFD2可有效抑制耐药肿瘤生长，具潜在治疗意义。研究创新性强，尤其在机制层面构建了表观-代谢-信号互作的新框架，但仍需进一步临床验证和安全性评估。

---

## 15. 胰腺癌：分子发病机制与新兴治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484057)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41484057
**DOI：** 10.1038/s41392-025-02499-y

### 第一部分 原文与翻译

**英文原标题：** Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease for which there is no effective treatment. A deep understanding of the mechanisms underlying the molecular pathogenesis, signaling pathways and risk factors leading to PDAC is of paramount importance for identifying novel targets, prognostic markers, preventive strategies, and signature markers for use in specific and personalized therapeutic procedures. Activating somatic mutations in the KRAS oncogene play a critical role in PDAC initiation and maintenance. Here, we highlight the complex interplay between KRAS signaling, the transcriptional coactivator YES1-associated protein (YAP) and Src family kinases (SFKs) in the pathogenesis of PDAC and drug sensitivity. We subsequently focused on diet-induced obesity, which has been correlated with an increased risk for developing PDAC in humans and mice and more severe clinical outcomes. Accumulating evidence also indicates that neural signals regulate critical functions of cancer cells, including their proliferation and dissemination, and that chronic stress promotes PDAC through the sympathetic nervous system via β-adrenergic receptors expressed by PDAC cells and other cells in the tumor microenvironment. Obesogenic mediators and stress neurotransmitters stimulate protein kinases, including PKA and PKD, which converge on CREB/ATF1 phosphorylation in PDAC cells. Since stress and obesity cooperate to promote the progression of PDAC, novel combinatorial strategies to prevent this devastating disease could be developed, repositioning FDA-approved drugs that are extensively used to treat cardiovascular and metabolic disorders and diseases. Finally, we review new advances in the treatment of PDAC, focusing on the discovery of novel drugs that directly inhibit KRAS and YAP function.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）是一种侵袭性极强且缺乏有效治疗手段的疾病。深入理解PDAC发生的分子发病机制、信号通路及危险因素，对于发现新的靶点、预后标志物、预防策略以及可用于特异化和个体化治疗的特征性标志物具有至关重要的意义。KRAS癌基因的激活性体细胞突变在PDAC的发生与维持过程中起关键作用。在本文中，我们重点强调KRAS信号、转录共激活因子YES1相关蛋白（YAP）及Src家族激酶（SFKs）之间在PDAC发病机制及药物敏感性中的复杂相互作用。随后，我们聚焦于饮食诱导的肥胖，其在人体和小鼠中均与PDAC发病风险升高及更严重的临床结局相关。越来越多的证据还表明，神经信号调控癌细胞的关键功能，包括其增殖和扩散；同时，慢性应激通过交感神经系统作用于PDAC细胞及肿瘤微环境中其他细胞所表达的β-肾上腺素能受体，从而促进PDAC的发展。促肥胖因子和应激性神经递质可激活蛋白激酶，包括PKA和PKD，这些信号在PDAC细胞内汇聚至CREB/ATF1的磷酸化。由于应激与肥胖协同促进PDAC进展，未来可以开发新的联合预防策略，重新定位那些已被FDA批准、广泛用于治疗心血管和代谢性疾病的药物以防治该毁灭性疾病。最后，我们回顾了PDAC治疗的最新进展，特别关注能直接抑制KRAS和YAP功能的新药研发。

### 第二部分 AI 大师评价

本文综述了胰腺导管腺癌的核心分子发病机制，强调了KRAS、YAP及Src家族激酶等关键信号网络在疾病发生与药物敏感性中的作用。作者系统探讨了肥胖和慢性应激如何通过神经与代谢通路协同促进PDAC进展，并提出了利用现有心代谢类药物进行疾病防控的潜在新思路。文章创新性地将代谢信号、神经调控与肿瘤生物学相结合，为未来多靶点干预策略提供了理论基础。但仍需进一步研究以验证这些机制及其在临床转化中的可行性。

---

## 16. 肽功能化膜伪装用于内源性硫化氢诱导的原位结直肠癌光热免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41484054)
**期刊：** Nature communications
**PMID：** 41484054
**DOI：** 10.1038/s41467-025-65876-9

### 第一部分 原文与翻译

**英文原标题：** Peptide-functionalized membrane camouflage for endogenous HS-induced photothermal immunotherapy of orthotopic colorectal cancer.

> **英文摘要：**
> The significant challenges pose by the high recurrence and metastasis rates of colorectal cancer (CRC) persist in its diagnosis and treatment. Activating innate immunity in CRC treatment has the potential to reduce drug resistance and side effects. Here, we develop a biomimetic platform by utilizing antimicrobial peptide-functionalized CRC cell membranes to encapsulate a cobalt-based metal-organic framework (C), hereby called peptide-functionalized camouflage C (PfCC). When injected into tumour-bearing mice, PfCC will degrade under the acidic condition of the tumour microenvironment and release cobalt ions, which react with endogenous HS to generate black stellate precipitates with good photothermal properties, recruiting NK cells and mitigates the immunosuppressive tumour-microenvironment. Simultaneously, the degradation of PfCC will release structure-protected antimicrobial peptides, inhibiting harmful bacteria, such as Desulfovibrio, and reducing HS production. The abovementioned synergistic top-down regulation of HS promote the polarization of macrophages and further activates the innate immune response. Moreover, experiments including the convex hull algorithm from AI deep learning of the segment anything model indicate that PfCC exhibites the most effective therapeutic effect compared with the single HS-regulated therapeutic modality. Taken together, PfCC represents a potential anti-cancer therapy for CRC with the combined effect of immune-regulation and the regulation of the gut flora.

> **中文摘要：**
> 结直肠癌（CRC）因其高复发率和高转移率，仍然在诊断和治疗上面临重大挑战。在CRC治疗中激活先天免疫有望减少药物耐受性和副作用。本研究构建了一种仿生平台，利用抗菌肽功能化的CRC细胞膜包裹钴基金属有机框架（C），命名为肽功能化伪装C（PfCC）。将PfCC注射入肿瘤负荷小鼠后，在肿瘤微环境的酸性条件下会发生降解并释放钴离子，这些离子与内源性硫化氢（HS）反应生成具有优良光热性能的黑色星状沉淀物，从而招募自然杀伤细胞，缓解免疫抑制性肿瘤微环境。同时，PfCC的降解释放出结构保护的抗菌肽，可抑制如硫杆菌属等有害菌并减少HS的生成。上述协同的自上而下HS调控促进了巨噬细胞极化并进一步激活先天免疫反应。此外，结合基于AI深度学习“Segment Anything”模型的凸包算法的实验表明，PfCC较单纯HS调控治疗模式显示出最显著的治疗效果。综上所述，PfCC作为一种结合免疫调节与肠道菌群调控作用的潜在抗CRC疗法，具有较高的应用前景。

### 第二部分 AI 大师评价

该研究旨在通过肽功能化的肿瘤细胞膜伪装纳米系统实现结直肠癌的光热免疫治疗。作者创新性地利用抗菌肽与钴基金属有机框架的协同作用，在酸性肿瘤环境下诱导内源性硫化氢反应以激活免疫系统并调节微生态。该策略同时实现了光热治疗、免疫增强及有害菌抑制的多重效应。实验结果显示其优于单一调控方式，具有显著综合疗效。但仍需进一步验证其长期安全性及在临床转化中的可控性。

---

## 17. 正视全球人工智能健康领域中的诊断鸿沟

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41483903)
**期刊：** Lancet (London, England)
**PMID：** 41483903
**DOI：** 10.1016/S0140-6736(25)02308-6

### 第一部分 原文与翻译

**英文原标题：** Confronting the diagnostic divide in global AI health.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文发表于《柳叶刀》，主要讨论全球范围内人工智能在医疗诊断领域存在的不平衡与差距问题。作者或旨在揭示不同地区在数据资源、算法适配性及基础设施建设上的不均衡现象，并强调这对医学公平性和临床应用普及的影响。该议题具前瞻性，突出了AI医疗发展中的伦理与社会挑战。然而，由于暂无摘要，具体方法与结论无法明确，需要进一步查阅全文以评估其实证深度与政策建议的可行性。

---

## 18. 1990–2023 年间 204 个国家和地区中女性亲密伴侣暴力与儿童性暴力所致疾病负担：全球疾病负担研究 2023 的系统分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41386261)
**期刊：** Lancet (London, England)
**PMID：** 41386261
**DOI：** 10.1016/S0140-6736(25)02503-6

### 第一部分 原文与翻译

**英文原标题：** Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

> **英文摘要：**
> BACKGROUND: Violence against women and against children are human rights violations with lasting harms to survivors and societies at large. Intimate partner violence (IPV) and sexual violence against children (SVAC) are two major forms of such abuse. Despite their wide-reaching effects on individual and community health, these risk factors have not been adequately prioritised as key drivers of global health burden. Comprehensive x§and reliable estimates of the comparative health burden of IPV and SVAC are urgently needed to inform investments in prevention and support for survivors at both national and global levels.
> 
> METHODS: We estimated the prevalence and attributable burden of IPV among females and SVAC among males and females for 204 countries and territories, by age and sex, from 1990 to 2023, as part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2023. We searched several global databases for data on self-reported exposure to IPV and SVAC and undertook a systematic review to identify the health outcomes associated with each of these risk factors. We modelled IPV and SVAC prevalence using spatiotemporal Gaussian process regression, applying data adjustments to account for measurement heterogeneity. We employed burden-of-proof methodology to estimate relative risks for outcomes associated with IPV and SVAC. These estimates informed the calculation of population attributable fractions, which were then used to quantify disability-adjusted life-years (DALYs) attributable to each risk factor.
> 
> FINDINGS: Globally, in 2023, we estimated that 608 million (95% uncertainty interval 518-724) females aged 15 years and older had ever been exposed to IPV, and 1·01 billion (0·764-1·48) individuals aged 15 years and older had experienced sexual violence during childhood. 18·5 million (8·74-30·0) DALYs were attributed to IPV among females and 32·2 million (16·4-52·5) DALYs were attributed to SVAC among males and females in 2023. IPV and SVAC were among the top contributors to the global disease burden in 2023, particularly among females aged 15-49 years, ranking as the fourth and fifth leading risk factors, respectively, for DALYs in this group. Among the eight health outcomes found to be associated with IPV, anxiety disorders and major depressive disorder were the leading causes of IPV-attributed DALYs, accounting for 5·43 million (-1·25 to 14·6) and 3·96 million (1·71 to 6·92) DALYs in 2023, respectively. SVAC was associated with 14 health outcomes, including mental health disorder, substance use disorder, and chronic and infectious disease outcomes. Self-harm and schizophrenia were the leading causes of SVAC-attributed burden, with SVAC accounting for 6·71 million (2·00 to 12·7) DALYs due to self-harm and 4·15 million (-1·92 to 13·1) DALYs due to schizophrenia in 2023.
> 
> INTERPRETATION: IPV and SVAC are substantial contributors to global health burden, and their health consequences span a variety of individual health outcomes. Importantly, mental health disorders account for the greatest share of disease burden among survivors. Investing in prevention of these avoidable risk factors has the potential to avert millions of DALYs and considerable premature mortality each year. Our findings represent strong evidence for global and national leaders to elevate IPV and SVAC among public health priorities. Sustained investments are needed to prevent IPV and SVAC and to implement interventions focused on supporting the complex social and health needs of survivors.
> 
> FUNDING: Gates Foundation.

> **中文摘要：**
> 背景：针对女性和儿童的暴力是侵犯人权的行为，会对幸存者和整个社会造成持久的危害。亲密伴侣暴力（IPV）与针对儿童的性暴力（SVAC）是此类虐待的两种主要形式。尽管这些风险因素对个人和群体健康具有广泛影响，但它们尚未被充分优先考虑为全球健康负担的关键驱动因素。亟需全面且可靠的IPV和SVAC相对健康负担估计，以指导在国家和全球层面上对预防与幸存者支持的投资。
> 
> 方法：作为《全球疾病、伤害与风险因素研究2023》的一部分，我们估算了1990年至2023年间204个国家和地区中，按年龄和性别划分的女性IPV和男女SVAC的流行率及其可归因负担。我们从多个全球数据库中检索了关于自我报告的IPV和SVAC暴露数据，并进行了系统综述，以确定与每一风险因素相关的健康结局。我们使用时空高斯过程回归模型估算IPV和SVAC的流行率，并对测量异质性进行了数据调整。我们采用“证据负担法”估算与IPV和SVAC相关健康结果的相对风险。这些估算结果用于计算人群归因分数，进而量化每个风险因素所致的伤残调整生命年（DALYs）。
> 
> 结果：2023年，全球估计有6.08亿（95%不确定性区间518–724）15岁及以上女性曾遭受过IPV，约有10.1亿（0.764–1.48）15岁及以上个体在童年时期经历过性暴力。2023年，女性IPV导致可归因DALYs为1850万（874万–3000万），而SVAC导致男女合计3220万（1640万–5250万）DALYs。IPV与SVAC在2023年是全球疾病负担的主要贡献者，尤其在15–49岁女性中，分别位列DALYs第四和第五大风险因素。在与IPV相关的八种健康结局中，焦虑障碍和重度抑郁障碍是主要DALYs来源，分别造成543万（−125万至1460万）和396万（171万至692万）DALYs。SVAC与14种健康结局有关，包括精神障碍、物质使用障碍以及慢性和感染性疾病。自残和精神分裂症是SVAC导致负担的首要原因，SVAC分别造成自残相关DALYs 671万（200万–1270万）和精神分裂症相关DALYs 415万（−192万至1310万）。
> 
> 解释：IPV和SVAC是全球健康负担的重要组成部分，其健康影响涵盖多种个体健康后果。尤其是，精神健康障碍构成幸存者疾病负担的最大部分。预防这些可避免风险因素的投资有望每年减少数百万DALYs并防止大量过早死亡。本研究结果为全球及国家层面的领导者提供了强有力的证据，促使他们将IPV和SVAC提升为公共卫生优先事项。需要持续投入以预防IPV和SVAC，并实施针对幸存者复杂社会与健康需求的干预措施。
> 
> 资金来源：盖茨基金会。

### 第二部分 AI 大师评价

本研究系统评估了1990–2023年间204个国家和地区女性亲密伴侣暴力及儿童期性暴力所致的全球疾病负担，基于GBD 2023数据，采用时空高斯过程回归与证据负担法综合建模。结果显示，这两种暴力对全球疾病负担贡献显著，尤其是精神健康障碍。研究创新之处在于首次同时量化两种性别暴力对全球DALYs的长期影响，为政策制定和资源分配提供重要依据，但仍受限于自我报告数据的偏倚与各国监测质量差异。

---

## 19. 共刺激阻断条件下的口服抗原暴露诱导调节性T细胞建立免疫耐受

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41117802)
**期刊：** The Journal of experimental medicine
**PMID：** 41117802
**DOI：** 10.1084/jem.20251635

### 第一部分 原文与翻译

**英文原标题：** Oral antigen exposure under costimulation blockade induces Treg cells to establish immune tolerance.

> **英文摘要：**
> Antigen-specific oral tolerance prevents harmful immune responses in naïve animals but is difficult to induce in antigen-primed hosts. Here, we showed that feeding of antigen-containing diet generated peripherally derived regulatory T (pTreg) cells with tissue-adapted effector properties. They acquired Treg-specific epigenomic changes at Treg signature genes, including Foxp3, exhibiting stable suppressive function. Cessation of antigen feeding diminished pTreg cells, hampering tolerance induction. Notably, pTreg cells induced by antigen feeding predominantly expressed CD101. CD101+ Treg cells with similar phenotypic and epigenetic features could also be generated in vitro from antigen-primed naïve CD4+ T cells by blocking CD28-mediated costimulation during TGF-β-dependent Treg induction. Furthermore, in mice already antigen-sensitized by nonoral routes, in vivo blockade of CD28 signaling with CTLA4-Ig prior to antigen feeding promoted differentiation of antigen-specific T cells into CD101+ pTreg cells, facilitating oral tolerance. Thus, continuous oral antigen exposure combined with CD28 blockade generates functionally stable CD101+ pTreg cells, thereby establishing systemic antigen-specific tolerance even in antigen-presensitized hosts.

> **中文摘要：**
> 抗原特异性的口服耐受可防止初始动物产生有害的免疫反应，但在已被抗原预敏的宿主中却难以诱导。在本研究中，我们发现喂食含抗原的饮食可产生具备组织适应性效应特征的外周来源调节性T（pTreg）细胞。这些细胞在包括Foxp3在内的调节性T细胞特征基因处获得了特异性的表观基因组改变，并表现出稳定的抑制功能。停止抗原喂食会导致pTreg细胞减少，从而阻碍耐受的建立。值得注意的是，由抗原喂食诱导的pTreg细胞主要表达CD101。在体外实验中，通过在TGF-β依赖的调节性T细胞诱导过程中阻断CD28介导的共刺激，也可从抗原预敏的初始CD4+ T细胞中产生具有相似表型和表观遗传特征的CD101+调节性T细胞。此外，在已通过非口服途径被抗原致敏的小鼠中，于抗原喂食前体内使用CTLA4-Ig阻断CD28信号，可促进抗原特异性T细胞分化为CD101+ pTreg细胞，从而促进口服耐受。因此，持续的口服抗原暴露结合CD28阻断可生成功能稳定的CD101+ pTreg细胞，即使在已预先致敏的宿主中也能建立系统性的抗原特异性耐受。

### 第二部分 AI 大师评价

该研究旨在探索如何在抗原预敏条件下诱导口服免疫耐受。作者通过结合口服抗原暴露与CD28信号阻断，成功诱导出功能稳定的CD101+外周调节性T细胞，并揭示了其在表观遗传层面的稳定性及免疫抑制特征。该发现不仅阐明了Treg细胞在耐受建立中的关键机制，也为治疗自身免疫病或过敏性疾病提供了新的免疫调控策略。然而，其在人体免疫系统中的可转化性仍需进一步验证。

---

## 20. 肺组织驻留记忆T细胞通过IL-10调控先天免疫以优化防御作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41081716)
**期刊：** The Journal of experimental medicine
**PMID：** 41081716
**DOI：** 10.1084/jem.20242307

### 第一部分 原文与翻译

**英文原标题：** Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity.

> **英文摘要：**
> Respiratory viral infections establish tissue-resident memory T cells (TRM) in the lung, which provide optimal protection against subsequent infections, though the underlying mechanisms are incompletely understood. Here, we demonstrate in a mouse model of heterosubtypic influenza infection that lung TRM attenuate inflammation by macrophages during secondary versus primary responses, in part, through production of the immunoregulatory cytokine IL-10. During secondary infections, lung TRM were the predominant producers of early IL-10; inhibiting early IL-10 signaling resulted in increased macrophage-mediated inflammation, morbidity, and lung pathology. Moreover, lung TRM were shown to directly modulate lung macrophage responses and polarization in depletion experiments. Finally, IL-10 enhanced IFN-γ production by lung memory CD8+ T cells. Human influenza-specific TRM isolated from lungs recapitulated robust IL-10 expression associated with augmented effector responses of murine TRM. These data support a dual role of TRM in coordinating in situ secondary responses-augmenting effector responses for robust viral clearance while dampening inflammation to limit tissue damage.

> **中文摘要：**
> 呼吸道病毒感染可在肺部建立组织驻留记忆T细胞（TRM），这些细胞对后续感染提供最佳防御，但其潜在机制尚未完全明了。在本研究中，我们在异亚型流感小鼠模型中证实，肺部TRM在继发反应相较于初次反应时，可通过产生免疫调节性细胞因子IL-10来部分抑制巨噬细胞介导的炎症。在继发感染过程中，肺部TRM是早期IL-10的主要来源；抑制早期IL-10信号可导致巨噬细胞介导的炎症、发病率及肺病理损伤的增加。此外，通过耗竭实验发现，肺部TRM可直接调控肺巨噬细胞的反应与极化。最后，IL-10可增强肺部记忆性CD8+T细胞的IFN-γ产生。来源于人肺的流感特异性TRM同样表现出强烈的IL-10表达，与小鼠TRM增强的效应反应一致。以上结果支持TRM在局部继发免疫应答中的双重作用——既增强效应性反应以促进病毒清除，又减弱炎症以限制组织损伤。

### 第二部分 AI 大师评价

该研究旨在阐明肺部组织驻留记忆T细胞（TRM）在继发呼吸道病毒感染中的免疫调控机制。作者利用异亚型流感小鼠模型，揭示了TRM通过IL-10分泌调控巨噬细胞炎症反应，从而在增强病毒清除的同时抑制组织损伤的平衡作用。研究还发现，IL-10能促进记忆性CD8+T细胞的IFN-γ产生，并在人类样本中得到验证。该工作创新性地揭示了IL-10依赖的TRM免疫调控机制，为改善抗病毒免疫与控制炎症损伤提供了潜在治疗启示，但仍需进一步探索其在人类疾病中的动态与可干预性。

---

## 21. 腺苷代谢清除通过许可RIPK1的精氨酸甲基化维持肝脏稳态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41081715)
**期刊：** The Journal of experimental medicine
**PMID：** 41081715
**DOI：** 10.1084/jem.20250603

### 第一部分 原文与翻译

**英文原标题：** Adenosine metabolic clearance maintains liver homeostasis by licensing arginine methylation of RIPK1.

> **英文摘要：**
> Tumor necrosis factor α (TNFα) maintains homeostasis through promoting cell survival or cell death; however, how this process is regulated by metabolic pathways remains largely unknown. Here, we identify adenosine kinase (ADK), the key enzyme for catalyzing the conversion of adenosine to AMP, as an endogenous suppressor of RIPK1 kinase. ADK-mediated adenosine metabolic clearance is a prerequisite for transmethylation reactions on various cellular targets. We found that ADK licenses constitutive R606 symmetric dimethylation in RIPK1 death domain (DD), which is catalyzed by protein arginine methyltransferase 5. Upon TNFα stimulation, DD-mediated RIPK1 dimerization is inhibited by R606 methylation, preventing RIPK1 kinase activation and keeping cell death in check. Both hepatocyte-specific ADK knockout and systemic ADK inhibition cause spontaneous RIPK1-driven hepatocyte death, which leads to hepatic homeostasis disruption. Furthermore, ADK is reduced in hepatic ischemia-reperfusion, aggravating hepatic injury during liver surgery. Thus, this study reveals a mechanism of adenosine metabolism-dependent homeostasis maintenance that is implicated in both physiological and pathological conditions.

> **中文摘要：**
> 肿瘤坏死因子α（TNFα）通过促进细胞存活或细胞死亡来维持稳态；然而，这一过程如何受到代谢途径的调控仍然 largely unknown。本文鉴定了腺苷激酶（ADK）这一催化腺苷转化为AMP的关键酶，作为RIPK1激酶的内源性抑制因子。ADK介导的腺苷代谢清除是多种细胞靶点上转甲基化反应的先决条件。研究发现，ADK允许RIPK1死亡结构域（DD）中R606位点的构成性对称二甲基化，该修饰由蛋白精氨酸甲基转移酶5催化。在TNFα刺激下，R606甲基化抑制了由DD介导的RIPK1二聚化，从而阻止RIPK1激酶的活化并控制细胞死亡。肝细胞特异性的ADK敲除或全身性ADK抑制均会引起由RIPK1驱动的自发性肝细胞死亡，导致肝脏稳态破坏。此外，在肝脏缺血再灌注过程中ADK水平降低，加重了肝脏手术中的肝损伤。因此，本研究揭示了一种依赖腺苷代谢的稳态维持机制，该机制在生理与病理状态下均具有重要意义。

### 第二部分 AI 大师评价

该研究旨在阐明代谢途径如何调控TNFα介导的细胞命运决策。作者通过分子与功能实验发现，腺苷激酶（ADK）通过促进腺苷清除，从而支持RIPK1在R606位点的甲基化修饰，进而抑制其二聚化与激酶活化，维持肝脏稳态。这一发现将腺苷代谢途径与细胞死亡信号网络相连接，为理解代谢与细胞命运调控的交叉机制提供了新视角。研究创新性在于首次揭示RIPK1甲基化与ADK代谢功能的因果关系，但其在其他组织及疾病模型中的普适性仍待深入探讨。

---

速递结束，祝您工作愉快！